Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab with etoposide and a platinum-based compound within its marketing authorisation for untreated extensive-stage small-cell lung cancer
Topic is suspended
 
Status Suspended
Process STA 2018
ID number 1509

Project Team

Project lead Louise Jafferally

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 October 2020 Committee meeting
08 July 2020 Suspended. Topic is suspended
08 July 2020 The company have announced that they will no longer be pursuing a Marketing Authorisation Application to the European Medicines Agency for Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer following the results of the KEYNOTE-604 trial data. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
07 February 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab in combination for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal will be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.
05 December 2019 - 10 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 December 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early- February 2020 when we will write to you about how you can get involved.
05 December 2019 Consultation on the draft scope and provisional matrix of consultees and commentators, with comments requested by 10 January 2020.
08 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Following an update from the company further information on the timelines for this appraisal will be available in due course.
22 March 2019 In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- July 2019 when we will write to you about how you can get involved.
14 November 2018 - 12 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance